Cellnovo Group (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announced today that it is partnering with the technology company, TypeZero, to utilise Cellnovo’s e- connected insulin patch pump alongside its inControl AP software in an artificial pancreas programme. This joint system will be in consideration for use in the International Diabetes Closed Loop Trial (IDCL), which is funded by the National Institute of Health (NIH), a part of the U.S. Department of Health Services.
The artificial pancreas is designed to automatically monitor and regulate blood-sugar levels in people with Type 1 diabetes through the delivery of insulin.